Vaccine Adjuvants Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Vaccine Adjuvants Market is Segmented by Type (Mineral Salt-based Adjuvant, Tensoactive Adjuvants, Adjuvant Emulsions, Liposome Adjuvants, Carbohydrate Adjuvants, Bacteria-derived Adjuvants, Virus-like Particles (VLP), and Other Types), Usage (Active Immunostimulants, Carriers, and Vehicle Adjuvants), Disease Type ( Infectious Disease and Cancer), Application (Research Applications and Commercial Applications), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Vaccine Adjuvants Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 13.37 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The vaccine adjuvants market is expected to witness a CAGR of 13.37% over the forecast period, 2022-2027.

The limitations on imports and exports due to facility closures during the COVID-19 pandemic had a short-term adverse impact on the market's growth in the pandemic’s preliminary phase due to supply chain disruptions and unavailability of human resources. However, the introduction of several vaccines for COVID-19 has impacted the market's growth positively in the post-pandemic phase. For instance, in July 2022, the United States Food and Drug Administration issued an emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, adjuvanted for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. Likewise, in July 2022, the United States Department of Health and Human Services (HHS), in collaboration with the Department of Defense (DOD), announced that it had secured 3.2 million doses of Novavax’s COVID-19 vaccine. The protein-based, adjuvanted vaccine will be made available for free to states, jurisdictions, federal pharmacy partners, and federally qualified health centers if it receives the United States Food and Drug Administration (FDA) Emergency Use Authorization (EUA) and recommendation from the Centers for Disease Control and Prevention (CDC). Therefore, such instances are likely to augment the market's growth in the near future.

Moreover, factors that promote the growth of the vaccine adjuvants market include unmet demand for specific vaccines, increasing government vaccination recommendations, technological advances, and increased use of combined and synthetic vaccines.

Globally, various government agencies are promoting and raising awareness about vaccinations against various diseases, such as anthrax, BCG, hepatitis, HPV, influenza, varicella, smallpox, and other conditions. In March 2021, the United States Department of Health and Human Services (HHS) invested nearly USD 10 billion to increase access to vaccines and better help communities of color, rural, low-income, and other marginalized communities in response to COVID-19. Such government initiatives on immunization in the country increase the use of vaccines, in turn positively impacting the vaccine adjuvants market's growth. Similarly, as per the article titled "Adjuvant Developed with NIH Funding Enhances Efficacy of India’s COVID-19 Vaccine" published in June 2021 by the National Institute of Allergy and Infectious Disease, the COVAXIN COVID-19 vaccine, which has been administered to about 25 million individuals in India and other countries to date, was made effective with the use of an adjuvant developed with funding from the National Institutes of Health. Alhydroxiquim-II, the adjuvant utilized in COVAXIN was developed and evaluated in the lab by the Lawrence, Kansas-based biotech company ViroVax LLC with funding provided by the NIAID Adjuvant Development Program.

Thus, these aforementioned factors are anticipated to boost the market’s growth over the forecast period. However, side effects and high toxicity of adjuvants, and the high R&D cost of developing a new adjuvant are expected to hinder the market’s growth.

Scope of the Report

As per the scope of the report, an adjuvant is a pharmacological or immunological agent that helps in synergizing and directing the adaptive immune response to a vaccine agent. Adjuvants are basically compounds that improve the body’s immunogenic reaction against antigens. Therefore, adjuvants are majorly added to vaccines to augment their capability to persuade long-term protection and safety against any kind of infection. The vaccine adjuvants market is segmented by type (mineral salt-based adjuvants, tensoactive adjuvants, adjuvant emulsions, liposome adjuvants, carbohydrate adjuvants, bacteria-derived adjuvants, virus-like particles (VLP), and other types), usage (active immunostimulants, carriers, and vehicle adjuvants), disease type ( infectious disease and cancer), application (research applications and commercial applications), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Type
Mineral Salt-based Adjuvant
Tensoactive Adjuvants
Adjuvant Emulsions
Liposome Adjuvants
Carbohydrate Adjuvants
Bacteria-derived Adjuvants
Virus-like Particles (VLP)
Other Types
By Usage
Active Immunostimulants
Vehicle Adjuvants
By Disease Type
Infectious Disease
By Application
Research Applications
Commercial Applications
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Mineral Salt-based Adjuvants Segment Expected to Witness the Highest CAGR During the Forecast Period

By type, the mineral salt-based adjuvants segment is expected to project significant growth over the forecast period. Alum vaccine supplements are the most widely used adjuvants in human vaccines. Aluminum salts include aluminum hydroxide, aluminum phosphate, and aluminum hydroxyphosphate. Aluminum-based salts are also used for research purposes to increase the effectiveness of vaccines.

Besides alum, calcium salts, iron, and zirconium are also frequently used as alternatives to alum salt. Calcium phosphate is regularly used in vaccines for diphtheria-tetanus-pertussis (DTP), polio, yellow fever, and BCG. It advertises soluble antigens and secretly expresses them in the immune system. As per an article titled "An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives" published in May 2021, aluminum salts are used as an adjuvant in most vaccinations that are currently approved by the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) for use in humans. These adjuvants are the ones that have been included in vaccine formulations the longest, and adding more adjuvants appears to be the only way to increase the safety and effectiveness of vaccines. Due to these characteristics, it is crucial to intensify the investigation of novel molecules and substances that have adjuvant qualities, as well as to boost the quantity of in vitro and in vivo investigations.

Therefore, ongoing research activities and the many benefits of mineral salt-based adjuvants in the vaccine, especially in the development of COVID-19 vaccines, are expected to further boost the segment’s growth over the forecast period.


North America Expected to Hold a Significant Market Share During the Forecast Period

North America is expected to observe significant growth in the market studied during the forecast period. The main factors driving the growth of the vaccine adjuvants market in the North American region are the presence of key market players, the availability of advanced technology, and the growing investment in R&D of vaccines. The market growth is boosted by several immunization programs, government and non-government initiatives, and an increase in demand for combined vaccines. For example, according to data published by the National Center for Immunization and Respiratory Diseases on June 9, 2022, retail pharmacies in the United States have administered and reported more than 254.3 million doses across programs, including 8 million doses administered onsite to long-term care facilities in the early days of the vaccination program.

Furthermore, according to the Centers for Disease Control and Prevention (CDC), adjuvants such as aluminum hydroxyphosphate sulfate, monophosphoryl lipid A (MPL) + aluminum salts, oil-based emulsions made from squalene, MPL, and -QS-21 (a natural compound from the Chilean soap tree incorporated in liposomal formulation), and cytosine phosphoguanine (CpG) are currently used in vaccines such as DtaP (Daptacel, Infanrix), Hep A (Havrix, Vaqta), Hep B (Engerix-B, Recombivax), HPV (Gardasil 9), Pneumococcal (Prevnar 13), Cervarix, Fluad, Shingrix, and Heplisav-B in the United States.

Therefore, owing to aforementioned factors the market of vaccine adjuvants is expected to augment over the analysis period.

Vaccine Adjuvants Market Growth

Competitive Landscape

The vaccine adjuvants market is moderately consolidated and consists of many major players. Companies such as Adjuvatis, GlaxoSmithKline PLC, Croda International PLC, Merck KGaA, and Novavax Inc. are the key players. The major companies have conducted product launches, approvals, acquisitions, and collaborations for the development of novel vaccine adjuvants, thereby building a competitive landscape in the market. For instance, in April 2020, GlaxoSmithKline PLC collaborated with Sanofi to develop an adjuvanted vaccine for COVID-19. Also, in the coming years, few other players are expected to enter the market owing to the high scope of expansion in the product portfolio globally.

Recent Developments

In February 2022, Sanofi and GSK intended to submit data from both their booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.

In August 2021, SK Bioscience and GlaxoSmithKline PLC (GSK) initiated a Phase 3 clinical study of SK’s COVID-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim Phase 1/2 results.

Table of Contents


    1. 1.1 Study Assumption and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Expanding Government Recommendations for Immunizations

      2. 4.2.2 Unmet Vaccine Market Needs for Certain Diseases

      3. 4.2.3 Increasing Use of Recombinant Subunit and Synthetic Vaccines

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects and High Toxicity of Adjuvants

      2. 4.3.2 High R&D Cost of Developing a New Adjuvant

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 5.1 By Type

      1. 5.1.1 Mineral Salt-based Adjuvant

      2. 5.1.2 Tensoactive Adjuvants

      3. 5.1.3 Adjuvant Emulsions

      4. 5.1.4 Liposome Adjuvants

      5. 5.1.5 Carbohydrate Adjuvants

      6. 5.1.6 Bacteria-derived Adjuvants

      7. 5.1.7 Virus-like Particles (VLP)

      8. 5.1.8 Other Types

    2. 5.2 By Usage

      1. 5.2.1 Active Immunostimulants

      2. 5.2.2 Carriers

      3. 5.2.3 Vehicle Adjuvants

    3. 5.3 By Disease Type

      1. 5.3.1 Infectious Disease

      2. 5.3.2 Cancer

    4. 5.4 By Application

      1. 5.4.1 Research Applications

      2. 5.4.2 Commercial Applications

    5. 5.5 Geography

      1. 5.5.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.5.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.5.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.5.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Adjuvance Tecchnologies Inc.

      2. 6.1.2 Adjuvatis

      3. 6.1.3 Agenus Inc.

      4. 6.1.4 Aphios Corporation

      5. 6.1.5 Chemtrade Logistics Inc.

      6. 6.1.6 Croda International PLC (Brenntag Biosector AS)

      7. 6.1.7 CSL Limited

      8. 6.1.8 Dynavax Technologies Corporation

      9. 6.1.9 GlaxoSmithKline PLC

      10. 6.1.10 InvivoGen

      11. 6.1.11 Merck KGaA

      12. 6.1.12 Novavax Inc.

      13. 6.1.13 OZ Biosciences

      14. 6.1.14 Pacific GeneTech Limited

      15. 6.1.15 Seppic (Air Liquide)

      16. 6.1.16 Thermo Fisher Scientific Inc.

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Vaccine Adjuvants Market market is studied from 2019 - 2027.

The Global Vaccine Adjuvants Market is growing at a CAGR of 13.37% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Adjuvatis, Merck KGaA, GlaxoSmithKline plc, Novavax Inc., Croda International plc are the major companies operating in Global Vaccine Adjuvants Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!